feature Detecting minimal residual disease in multiple myeloma Challenges and prospects for the integration of novel approaches in clinical practice

relapse rates in multiple myeloma (MM) remain high, even in patients who achieve complete response (CR). Lower minimal residual disease (MRD) levels correlate strongly with longer progressionfree survival, however the accuracy of MRD detection is strongly dependent upon the sensitivity of the techniques used. This review presents available data on MRD assays and their potential value in tailoring MM treatment. Available research shows that depth of response as assessed with current MRD evaluation methods is a powerful predictor of outcome, and may be more important than the manner in which a deep response was achieved. Kathleena sarty, Msc, is a student in the Department of medicine at Dalhousie University bryn robinson, PhD, is Clinical research manager in the maritime SPOr Support Unit sarah campbell, bsc, is research Coordinator in the maritime